RECARBRIO (Imipenem/Cilastatin/Relebactam) – CUTI & CIAI | HongKong DengYue Medicine

RECARBRIO Application Scope

• Indications:

  • Complicated urinary tract infections (cUTI), including pyelonephritis

  • Complicated intra-abdominal infections (cIAI)

  • Hospital-acquired bacterial pneumonia (HABP)

  • Ventilator-associated bacterial pneumonia (VABP)

• Therapeutic Area:

  • Antibiotics / Antibacterial therapy

• Mechanism:

  • Combines imipenem (carbapenem antibiotic), cilastatin (protects imipenem from renal metabolism), and relebactam (beta-lactamase inhibitor) → broad-spectrum antibacterial coverage, including multidrug-resistant Gram-negative bacteria.

    

RECARBRIO Characteristics

• Ingredients:

  • Imipenem (carbapenem antibacterial)

  • Cilastatin (renal dehydropeptidase inhibitor, protects imipenem)

  • Relebactam (beta-lactamase inhibitor)

• Properties:​ Sterile, white to yellowish powder for IV infusion after reconstitution.

• Packaging Specification:​ 1 vial contains imipenem 500 mg, cilastatin 500 mg, relebactam 250 mg; supplied in cartons of 1 vials.

• Storage:​ Store unopened vials at 2–8 °C (36–46 °F); protect from light. Do not freeze.

• Expiry Date: As printed on the carton/vial.

• Executive Standard: ​FDA Prescribing Information (latest revision).

• Approval Number: US NDA 212819.

• Date of Revision: June 2023 (latest FDA label).

• Manufacturer: Merck Sharp & Dohme Corp.

Guidelines for the Use of RECARBRIO

• Dosage and Administration:

  • Recommended Dose: 1.25 g IV q6h.

  • Administration: IV infusion only; reconstitute and further dilute before administration.

  • Missed Dose:​ Administer as soon as possible; then continue the regular dosing schedule.

• Adverse Reactions:

  • Common Adverse Reactions:

    • diarrhea

    • nausea

    • vomiting

    • headache

    • increased liver enzymes

    • infusion-site reactions

  • Serious Adverse Reactions:

    • seizures

    • hypersensitivity reactions (including anaphylaxis)

    • Clostridioides difficile–associated diarrhea

      ​

• Contraindications: Hypersensitivity to imipenem, cilastatin, relebactam, or other beta-lactam antibacterial drugs.

• Precautions:

  • Risk of seizures, especially in CNS disorders or renal impairment.

  • Monitor renal function; adjust dosage accordingly.

  • Monitor for signs of superinfection.

RECARBRIO Interactions

• Valproic acid/divalproex: serum concentrations may be reduced → loss of seizure control.

• Ganciclovir: may increase seizure risk when combined with imipenem.

• Other beta-lactams/antibiotics: potential additive hypersensitivity.

 

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
•  This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.